The effect of targeted agents on outcomes in patients with brain metastases from renal cell carcinoma treated with Gamma Knife surgery: Clinical article

Journal of Neurosurgery

Volumn 116, Issue 5, 2012, Pages 978-983

  Cochran, D Clay ^a   Chan, Michael D ^a   Aklilu, Mebea ^a   Lovato, James F ^a   Alphonse, Natalie K ^a   Bourland, J Daniel ^a   Urbanic, James J ^a   McMullen, Kevin P ^a   Shaw, Edward G ^a   Tatter, Stephen B ^a   Ellis, Thomas L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Brain metastasis; Renal cell carcinoma; Stereotactic radiosurgery; Targeted agent

Indexed keywords

BEVACIZUMAB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURGERY; FEMALE; GAMMA KNIFE RADIOSURGERY; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RADIATION INDUCED EDEMA; RADIATION INJURY; RADIATION NECROSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; PROTEIN-TYROSINE KINASES; RADIATION INJURIES; RADIOSURGERY; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT FAILURE;

EID: 84860740117     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2012.2.JNS111353     Document Type: Article

References (21)

1. DiBiase SJ, Valicenti RK, Schultz D, Xie Y, Gomella LG, Corn BW: Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol 158:746-749, 1997
2. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P: Renal cell carcinoma recurrence after nephrectomy for localized disease: predicting survival from time of recurrence. J Clin Oncol 24:3101-3106, 2006 (Pubitemid 46638947)
3. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134, 2007 (Pubitemid 46089673)
4. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655-1659, 2001 (Pubitemid 33126820)
5. Gaspar LE, Scott C, Murray K, Curran W: Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47:1001-1006, 2000 (Pubitemid 30345599)
6. Gore ME, Hariharan S, Porta C, Bracarda S, Hawkins R, Bjarnason GA, et al: Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 117:501-509, 2011
7. Hernandez L, Zamorano L, Sloan A, Fontanesi J, Lo S, Levin K, et al: Gamma knife radiosurgery for renal cell carcinoma brain metastases. J Neurosurg 97 (5 Suppl):489-493, 2002 (Pubitemid 35424332)
8. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281, 2007 (Pubitemid 46849157)
9. Jensen CA, Chan MD, McCoy TP, Bourland JD, deGuzman AF, Ellis TL, et al: Cavity-directed radiosurgery as adjuvant therapy after resection of a brain metastasis. Clinical article. J Neurosurg 114:1585-1591, 2011
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124, 2007 (Pubitemid 46089672)
11. Muacevic A, Kreth FW, Mack A, Tonn JC, Wowra B: Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim Invasive Neurosurg 47:203-208, 2004 (Pubitemid 39222818)
12. Nieder C, Spanne O, Nordøy T, Dalhaug A: Treatment of brain metastases from renal cell cancer. Urol Oncol 29:405-410, 2011
13. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al: Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 280:1485-1489, 1998 (Pubitemid 28507400)
14. Sawrie SM, Guthrie BL, Spencer SA, Nordal RA, Meredith RF, Markert JM, et al: Predictors of distant brain recurrence for patients with newly diagnosed brain metastases treated with stereotactic radiosurgery alone. Int J Radiat Oncol Biol Phys 70:181-186, 2008 (Pubitemid 350251044)
15. Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al: Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys 47:291-298, 2000 (Pubitemid 30236367)
16. Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD: Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control. J Neurosurg 98:342-349, 2003 (Pubitemid 36151030)
17. Shuto T, Inomori S, Fujino H, Nagano H: Gamma knife surgery for metastatic brain tumors from renal cell carcinoma. J Neurosurg 105:555-560, 2006 (Pubitemid 44525886)
18. Truman JP, García-Barros M, Kaag M, Hambardzumyan D, Stancevic B, Chan M, et al: Endothelial membrane remodeling is obligate for anti-angiogenic radiosensitization during tumor radiosurgery. PLoS One 5:e12310, 2010 [Erratum in PLoS One 5: doi: 10.1371/annotation/6e222ad5-b175-4a00-9d04-4d120568a897]
19. Vogl UM, Zehetgruber H, Dominkus M, Hejna M, Zielinski CC, Haitel A, et al: Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br J Cancer 95:691-698, 2006 (Pubitemid 44373483)
20. Wrónski M, Maor MH, Davis BJ, Sawaya R, Levin VA: External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M. D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37:753-759, 1997 (Pubitemid 27181304)
21. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003 (Pubitemid 36910021)